Mogrify, Ltd.
https://mogrify.co.uk
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mogrify, Ltd.
Astellas’s Venture Arm Is Focused On Flexibility But Avoiding Hype
VC Playbook: Bradley Hardiman, senior director of business development at Astellas Venture Management, discusses setting a CVC strategy when the biopharma market is in a “state of flux.”
Finance Watch: October Begins With A VC Mega-Round For Newly Named Iambic
Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.
Finance Watch: Dyno Therapeutics Raises $100m For Novel AAV Vectors
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.
Mogrify: Using Big Data To Transform Development Of Cell Therapies
Money in the bank, biotech legacies onboard, a fresh partnership, an emerging internal cell therapy pipeline and a grand vision for the broad-scale application of its technology – has Mogrify got it all? The biotech’s chief business officer, Karin Schmitt, talks to In Vivo about the group’s near- and long-term goals.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- Cell Mogrify Ltd
- Chondrogenix
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice